These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30821092)

  • 1. Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study.
    Song H; Zhong CS; Kieran MW; Chi SN; Wright KD; Huang JT
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27682. PubMed ID: 30821092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
    JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
    Lacroix JP; Wang B
    J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
    Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
    Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.
    Cavalieri S; Di Guardo L; Cimminiello C; Bono A; Tolomio E; Colombetti A; Valeri B; Di Tolla G; de Braud F; Del Vecchio M
    Tumori; 2016 Oct; 102(5):501-507. PubMed ID: 27470608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
    Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
    Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.
    Atkinson V; Long GV; Menzies AM; McArthur G; Carlino MS; Millward M; Roberts-Thomson R; Brady B; Kefford R; Haydon A; Cebon J
    Asia Pac J Clin Oncol; 2016 Dec; 12 Suppl 7():5-12. PubMed ID: 27905182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
    Drago JZ; Lawrence D; Livingstone E; Zimmer L; Chen T; Giobbie-Hurder A; Amann VC; Mangana J; Siano M; Zippelius A; Dummer R; Goldinger SM; Sullivan RJ
    Melanoma Res; 2019 Feb; 29(1):65-69. PubMed ID: 30376465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
    Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
    Lüdeke I; Terheyden P; Grisanti S; Lüke M
    Ophthalmologe; 2016 Oct; 113(10):861-863. PubMed ID: 26873702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
    Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
    Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Russo I; Zorzetto L; Frigo AC; Chiarion Sileni V; Alaibac M
    Eur J Dermatol; 2017 Oct; 27(5):482-486. PubMed ID: 29084636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.